Mechanistic study of the tumor suppressor role of MITF uncovers actionable translation targeting for prostate cancer

  • Pippa, Raffaella (PI)

Project Details


New therapies are urgently needed for men with advanced prostate cancer. The identification of novel therapeutic targets and pathways that contribute to prostate cancer lethality is necessary for improving clinical outcomes. Raffaella Pippa has discovered that microftalmia transcription factor (MITF), a transcription factor that regulates the expression of protein synthesis machinery, acts to prevents prostate cancer aggressiveness, and that MITF may become dysregulated in prostate cancer. In this project, Dr. Pippa will investigate the mechanisms by which MITF acts to limit prostate cancer progression in preclinical models. Whether MITF pathway activities may act as biomarkers to predict patient outcomes will be investigated. Pippa will also investigate the therapeutic potential for targeting protein synthesis machinery regulated by the MITF pathway in preclinical models of advanced prostate cancer, particularly in prostate cancer in which MITF is dysregulated. If successful, this project will determine the role of MITF in the pathogenesis of advanced prostate cancer and may lead to novel therapeutic approaches.
Effective start/end date1/01/19 → …


  • Prostate Cancer Foundation


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.